Study Notes on Enzyme Inhibition and Measurement Methods
Applied Pharm Chemistry Lecture 2: Enzyme Inhibition
Overview
Instructor: Dr. David Griffiths
Course Year: 2025/26
Topic: Enzyme inhibition and its measurement.
Learning Outcomes
Understanding of the following key concepts:
Inhibitor potency and how it is measured.
Comparison of different methods for measuring inhibition.
Definitions and applications of homologation and isosterism in drug development.
Jencks analysis concerning fragments or functional groups in molecules.
Measurement of Enzyme Inhibition
Previously discussed the inhibition of enzymes by measuring the effect of inhibitors/drugs on the Ki value.
Question posed: Are there other methods for the measurement of inhibition?
Answer: Yes.
IC50 (or I50) Measurement
Definition: IC50 is the concentration of the drug that results in 50% inhibition of enzymatic activity under specified experimental conditions.
It is noted that IC50 values are dependent on the specific experimental conditions utilized.
Variability of IC50 and ED50
In published studies, IC50 or ED50 values are often cited instead of the Ki value.
Key Point: IC50 values are experimental condition dependent and may vary between studies.
Relationship Between IC50 and Ki
Inquiry: Can IC50 be related to Ki?
Response: YES! They can be related.
Cheng-Prussoff Relationship
Termed as the Cheng-Prussoff relationship.
Equation: The relationship between IC50 and Ki for a conventional competitive inhibitor is given by:
If substrate concentration
is equal to , then:This means if you determine IC50 at , then .
Other Types of Inhibition
Similar relationships can be derived for other types of enzyme inhibition, although they may not be identical to the Cheng-Prussoff equation.
Request for Further Inquiry
If clarification or derivation of the Cheng-Prussoff equation is required, students are encouraged to seek assistance.
Drug Development Considerations
Coverage of competitive inhibitors includes discussion of how they are designed and the principles of homologation and isosterism in pharmacology.
Example: Anti-Hypertensives
Focus on ACE Inhibitors:
Hypertension is linked to increased renin release from the kidneys.
Treatment approach includes drugs that inhibit the formation of Angiotensin II (Ang II), which is formed from Angiotensin I (AT-I) by Angiotensin-Converting Enzyme (ACE) which is a significant drug target.
Role of ACE: ACE also inactivates the peptide bradykinin, which is involved in vasodilation and diuresis.
ACE Structure and Function
Classification: ACE is classified as a zinc metalloproteinase (specifically, a dipeptidyl carboxypeptidase).
Origin of ACE Inhibitors:
The first ACE inhibitors were derived from snake venoms, with SQ20881 (terprotide) being the most potent variant.
Notably, terprotide requires intravenous administration.
Inhibitors interact with the active site(s) of ACE.
Lead Compounds from Natural Products
Peptides isolated from Bothrops (Brazilian viper) venom serve as lead compounds in developing more effective ACE inhibitors.
Examples of peptide sequences exhibiting pharmacological effects and their structures were documented, showing variations of amino acids.
Potency and Stability of Peptides
Certain peptides can have strong inhibitory effects, completely blocking ACE activity at approximately .
A notable issue arises as these peptides are not orally stable; this is noted as a point for class consideration.
Analogues and Homologues
A series of analogues/homologues were synthesized to enhance stability and efficacy.
Example Compounds and their respective IC50 values (µM):
1. Succinate, C4 - 330
2. C5 - 70
3. α-methyl C4 - 22
4. α-methyl C5 - 4.9
5. β-methyl C5 - 1200
6. γ-methyl C5 - 260
Importance of Thiol Groups
The thiol group (SH) in Captopril, which binds effectively to at the ACE active site, is prone to oxidation.
The oxidation process converts the thiol to a disulfide (–S-S–), which negatively impacts pharmacokinetics and potency.
Further oxidation leads to inactive forms such as sulphenic and sulphonic acids.
Isosterism and Isosteric Replacement
Introduction of New Terms: Isosterism and isosteric replacement are introduced as vital concepts in drug design.
Definition: Isosteric alterations involve isovolumetric substitutions (similar volume) or isoelectronic substitutions (similar electron configuration).
Examples: Consider various groups such as COOH, CONH2, and NO2, or changes in ring structures, e.g., phenyl vs. pyridine.
Practical Applications of Isosterism
Consideration of specific dipeptide substitutions to demonstrate how different groups can exhibit isosteric properties.
Analysis of groups (e.g., CH3, NH2, OH, F) that maintain similar volumes and electron distributions, facilitating isosteric replacements.
Considerations for Workshop Discussion
Students are prompted to consider why certain structures might be considered isosteres of each other and the implications for drug design.
Discussion Topics: The significance of hydrolysable vs. non-hydrolysable analogues of ATP and related polyphosphate derivatives.
Final Lecture Notes
Upcoming topics will explore binding energies of fragments and atoms, their importance in drug design, and the Jencks' binding energy analysis.
Students are encouraged to review thermodynamic and kinetic principles from prior coursework to facilitate understanding in the next session.
Workshop Preparations
Essential tools to bring: ruler, eraser, calculator.
Discussion of problems from previous lectures: Determining the inhibition constant (Ki) graphically and algebraically, along with determining Km values.
Questions for Consideration
How to determine Ki using graphical and algebraic methods, including discussing under what situations one method may be preferred over another.